Treace Medical Concepts, Inc. (TMCI) Gross Margin
- Gross margin · 12 months: Value 79.45%; Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | 79.45% | Gross profit / revenue. Period ending 2026-06-30. $163.12M ÷ $205.31M × 100 ≈ 79.45% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | 163.12M USD | Gross Profit |
| Revenue | 205.31M USD | |
| Cost of products and services | 42.19M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | $163.12M | $205.31M | $42.19M | 79.45% |
| 2026-03-31 | $165.27M | $207.32M | $42.05M | 79.72% |
| 2025-12-31 | $169.75M | $212.69M | $42.94M | 79.81% |
| 2025-09-30 | $174.83M | $218.88M | $44.05M | 79.87% |
| 2025-06-30 | $171.25M | $213.75M | $42.50M | 80.12% |
| 2025-03-31 | $169.18M | $210.82M | $41.64M | 80.25% |
| 2024-12-31 | $168.26M | $209.36M | $41.09M | 80.37% |
| 2024-09-30 | $163.53M | $202.86M | $39.33M | 80.61% |
| 2024-06-30 | $160.16M | $198.53M | $38.38M | 80.67% |
| 2024-03-31 | $158.76M | $196.03M | $37.27M | 80.99% |
| 2023-12-31 | $151.94M | $187.12M | $35.18M | 81.20% |
| 2023-09-30 | $139.95M | $174.68M | $34.72M | 80.12% |
| 2023-06-30 | $134.16M | $166.97M | $32.82M | 80.35% |
| 2023-03-31 | $124.55M | $154.99M | $30.43M | 80.36% |
| 2022-12-31 | $114.31M | $141.84M | $27.52M | 80.60% |
| 2022-09-30 | $101.42M | $125.51M | $24.09M | 80.81% |
| 2022-06-30 | $92.36M | $114.07M | $21.71M | 80.97% |
| 2022-03-31 | $84.75M | $104.76M | $20.00M | 80.90% |
| 2021-12-31 | $76.59M | $94.42M | $17.83M | 81.12% |
| 2021-09-30 | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) |
| 2020-12-31 | $44.90M | $57.37M | $12.47M | 78.26% |
| 2020-09-30 | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) |
| 2019-12-31 | $31.79M | $39.42M | $7.63M | 80.64% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |